STATEMENT PURSUANT TO GENERAL INSTRUCTION E
OF FORM S-8 “REGISTRATION OF ADDITIONAL SECURITIES”
Endocyte, Inc. (the “Registrant”) filed a Registration Statement on Form S-8 (File No. 333-172121) with the Securities and Exchange Commission (the “Commission”) on February 9, 2011 (the “Initial Registration Statement”), which registered shares of the Registrant’s Common Stock, par value $0.001 per share (the “Common Stock”) available for issuance under the Endocyte, Inc. 2010 Equity Incentive Plan (the “2010 EIP”) among other plans. Pursuant to General Instruction E to Form S-8, the contents of the Initial Registration Statement are incorporated herein by reference.
The Registrant has filed this Form S-8 Registration Statement (this “Registration Statement”) to register: (i) 847,000 additional shares of Common Stock, not previously registered, under the 2010 EIP that are available for issuance under the 2010 EIP based on approval by the Registrant’s Board of Directors on November 3, 2016 pursuant to the automatic share reserve increase provision of the 2010 EIP (such shares, the “Additional 2010 EIP Shares”); (ii) 1,884 shares of Common Stock, not previously registered, under the 2010 EIP, that were subject to awards that expired or were otherwise terminated without having been exercised in full, or were forfeited to or repurchased by the Registrant, under the Registrant’s 1997 Stock Plan (the “1997 Plan”) (such shares, the “Newly Available 1997 Plan Shares”) through February 28, 2017; and (iii) 15,860 shares of Common Stock, not previously registered, under the 2010 EIP, that were subject to awards that expired or were otherwise terminated without having been exercised in full, or were forfeited to or repurchased by the Registrant, under the Registrant’s 2007 Stock Plan (the “2007 Plan”) (such shares, the “Newly Available 2007 Plan Shares”) through February 28, 2017. The 2010 EIP provides, among other things, that any shares of Common Stock subject to outstanding awards under the 1997 Plan or the 2007 Plan that expire, terminate, are forfeited or are repurchased are available for issuance under the 2010 EIP, subject to certain limitations. The Newly Available 1997 Plan Shares and the Newly Available 2007 Plan Shares were previously registered by the Registrant on the Initial Registration Statement. Concurrently with the filing of this Registration Statement, the Registrant is filing a post-effective amendment to the Initial Registration Statement deregistering the Newly Available 1997 Plan Shares and the Newly Available 2007 Plan Shares that are being carried forward under this Registration Statement.
This Registration Statement is hereby filed to reflect that, following the date hereof, the Additional 2010 EIP Shares, the Newly Available 1997 Plan Shares and the Newly Available 2007 Plan Shares are registered under the 2010 EIP.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
The list of Exhibits is incorporated herein by reference to the Index to Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of West Lafayette, State of Indiana, on March 14, 2017.
Icha
|
|
|
|
|
Endocyte, Inc.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Michael A. Sherman
|
|
|
|
Michael A. Sherman,
|
|
|
|
President and Chief Executive Officer
|
|
POWER OF ATTORNEY
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in their respective capacities and on the respective dates indicated opposite their names. Each person whose signature appears below hereby authorizes Michael A. Sherman and Michael T. Andriole, or either of them, each with full power of substitution, to execute in the name and on behalf of such person any amendment to this Registration Statement, including post-effective amendments, and to file the same, with exhibits thereto, and other documents in connection therewith, making such changes in this Registration Statement as the Registrant deems appropriate, and appoints each of Michael A. Sherman and Michael T. Andriole, each with full power of substitution, attorney-in-fact to sign any amendment and any post-effective amendment to this Registration Statement and to file the same, with exhibits thereto, and other documents in connection therewith.
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Michael A. Sherman
|
|
Director, President and Chief Executive Officer
|
|
March 14, 2017
|
Michael A. Sherman
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Michael T. Andriole
|
|
Chief Financial Officer
|
|
March 14, 2017
|
Michael T. Andriole
|
|
(Principal Financial Officer)
|
|
|
|
|
|
|
|
/s/ Beth A. Taylor
|
|
Vice President of Finance and Chief Accounting Officer
|
|
March 14, 2017
|
Beth A. Taylor
|
|
(Principal Accounting Officer)
|
|
|
|
|
|
|
|
/s/ John C. Aplin
|
|
Chairman of the Board of Directors
|
|
March 14, 2017
|
John C. Aplin
|
|
|
|
|
|
|
|
|
|
/s/ Philip S. Low
|
|
Director and Chief Science Officer
|
|
March 14, 2017
|
Philip S. Low
|
|
|
|
|
|
|
|
|
|
/s/ Keith E. Brauer
|
|
Director
|
|
March 14, 2017
|
Keith E. Brauer
|
|
|
|
|
|
|
|
|
|
/s/ Colin Goddard
|
|
Director
|
|
March 14, 2017
|
Colin Goddard
|
|
|
|
|
|
|
|
|
|
/s/ Ann F. Hanham
|
|
Director
|
|
March 14, 2017
|
Ann F. Hanham
|
|
|
|
|
|
|
|
|
|
/s/ Marc D. Kozin
|
|
Director
|
|
March 14, 2017
|
Marc D. Kozin
|
|
|
|
|
|
|
|
|
|